Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Annabel Samimy
STIF

Annabel Samimy

Stifel Nicolaus
Wall Street Analyst
★★★☆☆
#2222
on 13Foresight · ranked by our own returns
36%
Success Rate
-8.6%
Average Return
20 of 56 calls profitable · -12.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 36% of Annabel Samimy's ratings turned a profit when each position was held for 1 year — averaging -8.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

83 Buy 7 Hold 0 Sell
Annabel's Stock Coverage 30 ratings · 2026-11-09
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
LGND
Ligand Pharma
 Oct 30, 2026 BUY Strong Buy
-11.1% avg upside
16 analysts
$350.00
8.37% Upside
 -5.1% ·
SUPN
Supernus Pharmaceuticals
 Oct 30, 2026 HOLD Strong Buy
+30.3% avg upside
9 analysts
$55.00
31.21% Upside
 -4.7% ·
VKTX
Viking Therapeutics
 Oct 29, 2026 BUY Strong Buy
+172.0% avg upside
31 analysts
$95.00
248.22% Upside
 +0.1% ·
RGNX
RegenXBio
 Oct 21, 2026 BUY Strong Buy
+389.8% avg upside
25 analysts
$42.00
483.40% Upside
 +7.1% ·
EYPT
EyePoint Pharmaceuticals
 Oct 20, 2026 BUY Buy
+3222.9% avg upside
21 analysts
$6.00
1622.10% Upside
 -12.2% ·
MBX
MBX Biosciences, Inc.
 Oct 12, 2026 BUY Strong Buy
+53.5% avg upside
14 analysts
$84.00
50.36% Upside
 -1.7% ·
OCS
Oculis Holding
 Sep 28, 2026 BUY Strong Buy
+367.8% avg upside
11 analysts
$40.00
384.21% Upside
 -17.3% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Sep 24, 2026 BUY Strong Buy
+122.3% avg upside
11 analysts
$34.94
266.98% Upside
 -17.2% ·
IVA
Inventiva
 Sep 23, 2026 BUY Strong Buy
+350.3% avg upside
17 analysts
$15.00
310.95% Upside
 +9.0% ·
TRVI
Trevi Therapeutics
 Aug 07, 2026 BUY Strong Buy
+75.4% avg upside
18 analysts
$30.00
121.28% Upside
 -30.8% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Aug 07, 2026 BUY Strong Buy
+373.2% avg upside
17 analysts
$90.00
311.47% Upside
 -64.1% ·
EOLS
Evolus
 Aug 06, 2026 BUY Strong Buy
+93.2% avg upside
9 analysts
$17.00
131.39% Upside
 -3.4% ·
JAZZ
Jazz Pharmaceuticals
 Aug 04, 2026 BUY Strong Buy
+16.2% avg upside
36 analysts
$275.00
27.37% Upside
 -10.3% ·
PVLA
Palvella Therapeutics
 Jun 24, 2026 BUY Strong Buy
+17.8% avg upside
28 analysts
$250.00
71.03% Upside
 +34.3% ·
MLYS
Mineralys Therapeutics, Inc.
 May 07, 2026 BUY Strong Buy
+150.8% avg upside
12 analysts
$52.00
186.07% Upside
 -47.8% ·
PHAT
Phathom Pharmaceuticals
 Jan 15, 2026 BUY Strong Buy
+316.6% avg upside
15 analysts
$28.00
387.83% Upside
 -65.0% ·
ALT
Altimmune
 Dec 19, 2025 BUY Strong Buy
+1191.4% avg upside
20 analysts
 — -47.7% ·
RANI
Rani Therapeutics Holdings
 Apr 01, 2025 BUY Strong Buy
+1444.2% avg upside
10 analysts
$8.00
1255.90% Upside
 -34.5% ·
IL:KMDA
Kamada
 Jan 08, 2025 BUY Strong Buy
+62.6% avg upside
7 analysts
 — -3.3% ·
TVRD
Tvardi Therapeutics
 Dec 19, 2024 HOLD Strong Buy
+2090.0% avg upside
24 analysts
 — -73.0% ·
KYNB
Kyntra Bio
 Aug 30, 2023 HOLD Buy
+615.9% avg upside
17 analysts
$11.00
140.73% Upside
 -62.3% ·
TSE:BHC
Bausch Health Companies
 Nov 03, 2022 BUY Buy
+386.9% avg upside
30 analysts
$19.57
70.52% Upside
 +16.8% ·
EVFM
Evofem Biosciences
 Oct 19, 2022 HOLD Buy
+381150.0% avg upside
8 analysts
$62.50
1041566.68% Upside
 · ·
ELTX
Elicio Therapeutics
 Jun 30, 2022 HOLD Buy
+730.6% avg upside
11 analysts
$15.00
792.81% Upside
 -16.7% ·
TXMD
TherapeuticsMD
 May 06, 2021 BUY Buy
+247.3% avg upside
8 analysts
$5.00
177.86% Upside
 · ·
PRGO
Perrigo Company
 Aug 09, 2018 HOLD Buy
+333.3% avg upside
20 analysts
$87.00
451.28% Upside
 -32.1% ·
RMTI
Rockwell Med
 Nov 07, 2016 HOLD Hold
+93.1% avg upside
11 analysts
$7.00
1.04% Downside
 · ·
CORT
Corcept Therapeutics
 Jan 13, 2014 HOLD Buy
-17.8% avg upside
16 analysts
 — · ·
ARCT
Arcturus Therapeutics
 Dec 04, 2013 BUY Buy
+175.7% avg upside
36 analysts
$27.00
144.69% Upside
 -80.9% ·
HAL
Halliburton
 Oct 18, 2011 BUY Strong Buy
+16.0% avg upside
42 analysts
$56.00
54.92% Upside
 +2.1% ·
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Annabel Samimy — Frequently Asked Questions
How accurate are Annabel Samimy's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Annabel's ratings were profitable over a one-year hold, with an average return of -8.6% per rating, or +18.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Annabel ranked on 13Foresight?
Annabel Samimy is currently ranked #2222 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Annabel cover?
Annabel most recently has ratings on LGND, SUPN, VKTX, RGNX, EYPT, MBX, OCS, TSE:EPRX, IVA, TRVI, GPCR, EOLS and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.